Finance

Lists
Why is ENTA down ၃.၄၁%?
Dive Deeper
ENTA:NASDAQ
Enanta Pharmaceuticals Inc
၁၂.၁၇ US$
-၃.၄၁%
(-၀.၄၃) 1D
၁၂.၁၇ US$
၀.၀၀% (၀.၀၀)
After hours
Closed: အောက် ၆, GMT-၄ ၁၆:၀၀:၀၁  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ENTA...
Open
၁၂.၆၆ US$
High
၁၂.၆၆ US$
Low
၁၁.၉၇ US$
Mkt. cap
၃၆.၄၆ ကုဋေ
Avg. vol.
၂.၈၃ သိန်း
Volume
၂.၇၂ သိန်း
52-wk high
၁၇.၁၅ US$
52-wk low
၁၀.၂၀ US$
EPS
-၂.၄၁ US$
Beta
၀.၉၆
Shares outstanding
၂.၉၁ ကုဋေ
No. of employees
၁၂၀
Open
၁၂.၆၆ US$
High
၁၂.၆၆ US$
Low
၁၁.၉၇ US$
Mkt. cap
၃၆.၄၆ ကုဋေ
Avg. vol.
၂.၈၃ သိန်း
Volume
၂.၇၂ သိန်း
52-wk high
၁၇.၁၅ US$
52-wk low
၁၀.၂၀ US$
EPS
-၂.၄၁ US$
Beta
၀.၉၆
Shares outstanding
၂.၉၁ ကုဋေ
No. of employees
၁၂၀
News stories
From web sources and news partners
AD HOC NEWS
AD HOC NEWS
·
ပြီးခဲ့သည့် ၁ ရက်
Enanta Pharmaceuticals stock fell 2.78 percent on October 5
About Enanta Pharmaceuticals Inc
CEO-
Employees၁၂၀
Founded၁၉၉၅
HeadquartersWatertown, မက်ဆာချူးဆက်ပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websiteenanta.com
Analyst ratings
Based on 1 analyst giving stock ratings to ENTA in the past 3 months
Buy
Buy
1
Hold
0
Sell
0
12-month forecast
Based on 1 Wall Street analyst offering 12-month price targets for ENTA in the last 3 months
Highest
Current ၁၂.၁၇ US$
၂၀.၀၀ US$ (+၆၄.၃၄%)
Average
၂၀.၀၀ US$ (+၆၄.၃၄%)
Lowest
၂၀.၀၀ US$ (+၆၄.၃၄%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brandon Folkes
H.C. Wainwright
Buy
Reiterated
၂၀.၀၀ US$
+၆၄.၃%
09/23/2026
Unknown Analyst
Rodman & Renshaw
Buy
Initiated
၂၀.၀၀ US$
+၆၄.၃%
03/26/2026
Anupam Rama
J.P. Morgan
Buy
Maintained
၁၉.၀၀ US$
+၅၆.၁%
03/03/2026
Last report
၂၀၂၆ ဩ ၁၀
Fiscal period
Q3 2026
-၀.၆၇ US$ / -၀.၅၄ US$
-၂၅.၂၃%miss
Revenue / Est. (USD)
၁.၄၄ ကုဋေ / ၁.၆၄ ကုဋေ
-၁၂.၂၈%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
၁.၅၁ ကုဋေ
၁.၈၆ ကုဋေ
၁.၇၂ ကုဋေ
၁.၄၄ ကုဋေ
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
၂.၃၈ ကုဋေ
၂.၀၉ ကုဋေ
၁.၉၄ ကုဋေ
၂.၂၁ ကုဋေ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၉.၇၀ သန်း
၉.၀၁ သန်း
၉.၅၇ သန်း
၉.၄၇ သန်း
Operating expense
၃.၃၅ ကုဋေ
၂.၉၉ ကုဋေ
၂.၉၀ ကုဋေ
၃.၁၆ ကုဋေ
Total operating expenses
၃.၃၅ ကုဋေ
၂.၉၉ ကုဋေ
၂.၉၀ ကုဋေ
၃.၁၆ ကုဋေ
Operating income
-၁.၈၄ ကုဋေ
-၁.၁၃ ကုဋေ
-၁.၁၉ ကုဋေ
-၁.၇၂ ကုဋေ
Other non operating income
၃.၉၀ သောင်း
-
-
-
EBT including unusual items
-၁.၈၇ ကုဋေ
-၁.၁၉ ကုဋေ
-၁.၃၁ ကုဋေ
-၁.၉၅ ကုဋေ
EBT excluding unusual items
-၁.၉၆ ကုဋေ
-၁.၁၉ ကုဋေ
-၁.၃၁ ကုဋေ
-၁.၉၅ ကုဋေ
Income tax expense
၃.၂၀ သောင်း
၂.၄၀ သောင်း
၇.၀၀ ထောင်
၃.၆၀ သောင်း
Effective tax rate
-၀.၁၇%
-၀.၂၀%
-၀.၀၅%
-၀.၁၈%
Other operating expenses
-
-
-
-
Net income
-၁.၈၇ ကုဋေ
-၁.၁၉ ကုဋေ
-၁.၃၁ ကုဋေ
-၁.၉၅ ကုဋေ
Net profit margin
-၁၂၃.၆၄%
-၆၄.၁၃%
-၇၆.၂၉%
-၁၃၅.၈၁%
Earnings per share
-၀.၈၇
-၀.၄၂
-၀.၄၅
-၀.၆၇
Interest and investment income
၁.၁၁ သန်း
၂.၄၄ သန်း
၂.၀၈ သန်း
၁.၉၀ သန်း
Interest expense
-၂.၃၉ သန်း
-၃.၀၈ သန်း
-၃.၃၂ သန်း
-၄.၁၃ သန်း
Net interest expenses
-၁.၂၈ သန်း
-၆.၄၁ သိန်း
-၁.၂၃ သန်း
-၂.၂၃ သန်း
Depreciation and amortization charges
-
-
-
-
EBITDA
-၁.၇၁ ကုဋေ
-၁.၀၀ ကုဋေ
-၁.၀၆ ကုဋေ
-၁.၆၁ ကုဋေ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google အက်ပ်များ